CpG has been shown to induce a Th1‐biased immune response and support CD8+ T cell responses, enabling them to be the promising adjuvants for cancer vaccines.33, 34, 35 However, the tumor elimination efficiency of CpG‐based vaccines is usually counteracted by the immunosuppressive microenvironment of the established tumors. The gene discussed is CD8A; the disease is neoplasm.